Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan and miRNAs in Refractory Heart Failure
NCT04950569Phase 4Unknown
- Sponsor
- Tongji Hospital
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levosimendan in heart failure (HF) (2 arms), sponsored by Tongji Hospital. Primary endpoint: N-terminal pro-brain natriuretic peptide at 7 days. Status: unknown.
02
Drugs
levosimendan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04950569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950569.